The world’s first mRNA lung cancer vaccine, BNT116, developed by BioNTech, is in phase 1 human trials across seven countries, targeting non-small cell lung cancer (NSCLC). Using mRNA technology similar to COVID-19 vaccines, it trains the immune system to attack cancer cells while sparing healthy tissue. The trial involves 130 patients, including 20 in the UK, and combines weekly vaccine doses with immunotherapy to treat tumors and prevent recurrence. If successful, it could revolutionize personalized cancer treatment and improve survival rates globally.